{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:10:27Z","timestamp":1760184627356,"version":"build-2065373602"},"reference-count":114,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.rdc.2023.01.001","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T08:08:29Z","timestamp":1677658109000},"page":"193-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Approach to Systemic Sclerosis Patient Assessment"],"prefix":"10.1016","volume":"49","author":[{"given":"Sindhu R.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Foeldvari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rdc.2023.01.001_bib1","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/art.23018","article-title":"Classification criteria in rheumatic diseases: a review of methodologic properties","volume":"57","author":"Johnson","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.rdc.2023.01.001_bib2","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/acr.24609","article-title":"Differences sustained between diffuse and limited forms of juvenile systemic sclerosis in expanded international cohort","volume":"74","author":"Foeldvari","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.rdc.2023.01.001_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MD.0000000000000018","article-title":"Early- versus late-onset systemic sclerosis: differences in clinical presentation and outcome in 1037 patients","volume":"93","author":"Alba","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.rdc.2023.01.001_bib4","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.3899\/jrheum.140006","article-title":"The effect of male sex on survival in systemic sclerosis","volume":"41","author":"Hussein","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13075-016-0933-1","article-title":"Sex disparities in systemic sclerosis-associated pulmonary arterial hypertension: a cohort study","volume":"18","author":"Pasarikovski","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rdc.2023.01.001_bib6","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3899\/jrheum.080915","article-title":"Ethnic influence on disease manifestations and autoantibodies in Chinese-descent patients with systemic sclerosis","volume":"36","author":"Low","year":"2009","journal-title":"J\u00a0Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2023.01.001_bib7","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3899\/jrheum.180042","article-title":"Ethnic variations in systemic sclerosis disease manifestations, internal organ involvement, and mortality","volume":"46","author":"Al-Sheikh","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib8","first-page":"1117","article-title":"Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases","volume":"33","author":"Johnson","year":"2006","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib9","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1136\/ard.57.11.682","article-title":"Mortality and causes of death in a Swedish series of systemic sclerosis patients","volume":"57","author":"Hesselstrand","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2023.01.001_bib10","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/rheumatology\/37.7.750","article-title":"Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma)","volume":"37","author":"Jacobsen","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib11","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/acr.22583","article-title":"Distinctions between diagnostic and classification criteria?","volume":"67","author":"Aggarwal","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.rdc.2023.01.001_bib12","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.23015","article-title":"Classification criteria for rheumatic diseases: why and how?","volume":"57","author":"Dougados","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2023.01.001_bib13","first-page":"840","article-title":"Classification in systemic sclerosis","volume":"33","author":"Johnson","year":"2006","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib14","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.3899\/jrheum.201594","article-title":"Systematic analysis of the literature in search of defining systemic sclerosis subsets","volume":"48","author":"Nevskaya","year":"2021","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib15","first-page":"1855","article-title":"Classification criteria for systemic sclerosis subsets","volume":"34","author":"Johnson","year":"2007","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib16","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2023.01.001_bib17","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2023.01.001_bib18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.rdc.2015.04.003","article-title":"New classification criteria for systemic sclerosis (Scleroderma)","volume":"41","author":"Pope","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.rdc.2023.01.001_bib19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11926-015-0506-3","article-title":"New ACR EULAR guidelines for systemic sclerosis classification","volume":"17","author":"Johnson","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.rdc.2023.01.001_bib20","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/acr.20684","article-title":"Validation of potential classification criteria for systemic sclerosis","volume":"64","author":"Johnson","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.rdc.2023.01.001_bib21","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jclinepi.2013.12.009","article-title":"Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria","volume":"67","author":"Johnson","year":"2014","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.rdc.2023.01.001_bib22","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/acr.20679","article-title":"Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise","volume":"64","author":"Fransen","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.rdc.2023.01.001_bib23","first-page":"24","article-title":"A\u00a0Delphi exercise and cluster analysis to aid in the development of potential classification criteria for systemic sclerosis using SSc experts and databases","volume":"31","author":"Coulter","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib24","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","article-title":"Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee","volume":"23","year":"1980","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2023.01.001_bib25","first-page":"1","article-title":"Preliminary criteria for the classification of systemic sclerosis (scleroderma)","volume":"31","year":"1981","journal-title":"Bull Rheum Dis"},{"key":"10.1016\/j.rdc.2023.01.001_bib26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/pgmj.64.748.121","article-title":"The diagnosis and classification of scleroderma (systemic sclerosis)","volume":"64","author":"Barnett","year":"1988","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.rdc.2023.01.001_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0307-742X(21)00052-7","article-title":"Methods and preliminary results of the scleroderma criteria cooperative study of the American Rheumatology Association","volume":"5","author":"Masi","year":"1979","journal-title":"Clin Rheum Dis"},{"key":"10.1016\/j.rdc.2023.01.001_bib28","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/rheumatology\/keu530","article-title":"Performance of the new ACR\/EULAR classification criteria for systemic sclerosis in clinical practice","volume":"54","author":"Jordan","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.rdc.2023.01.001_bib29","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/acr.22451","article-title":"The 2013 ACR\/EULAR Classification Criteria for Systemic Sclerosis Out-perform the 1980 Criteria. Data from the Canadian Scleroderma Research Group","volume":"67","author":"Alhajeri","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.rdc.2023.01.001_bib30","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3899\/jrheum.140047","article-title":"Performance of the 2013 American College of Rheumatology\/European League Against Rheumatism Classification Criteria for Systemic Sclerosis (SSc) in large, well-defined cohorts of SSc and mixed connective tissue disease","volume":"42","author":"Hoffmann-Vold","year":"2015","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib31","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.semarthrit.2016.05.007","article-title":"Validation of the 2013 American College of Rheumatology\/European League Against Rheumatism classification criteria for systemic sclerosis in patients from a capillaroscopy clinic","volume":"46","author":"Melchor","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2023.01.001_bib32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.22551","article-title":"The Pediatric Rheumatology European Society\/American College of Rheumatology\/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis","volume":"57","author":"Zulian","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2023.01.001_bib33","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib34","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5301\/jsrd.5000216","article-title":"Limited cutaneous systemic sclerosis: the unfairly neglected subset","volume":"1","author":"Allanore","year":"2016","journal-title":"J\u00a0Scleroderma Relat Disord"},{"key":"10.1016\/j.rdc.2023.01.001_bib35","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/ard.2010.136929","article-title":"Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group","volume":"70","author":"Avouac","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2023.01.001_bib36","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/annrheumdis-2012-202295","article-title":"Very early versus early disease: the evolving definition of the 'many faces' of systemic sclerosis","volume":"72","author":"Matucci-Cerinic","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2023.01.001_bib37","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1136\/annrheumdis-2013-203716","article-title":"Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis","volume":"73","author":"Minier","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 125","key":"10.1016\/j.rdc.2023.01.001_bib38","first-page":"40","article-title":"Systemic sclerosis Progression INvestiGation (SPRING) Italian registry: demographic and clinico-serological features of the scleroderma spectrum","volume":"38","author":"Ferri","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00296-011-2359-z","article-title":"ANCA-associated vasculitis in systemic sclerosis report of 3 cases","volume":"33","author":"Omair","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.rdc.2023.01.001_bib40","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.3899\/jrheum.170953","article-title":"Epidemiology and survival of systemic sclerosis-systemic lupus erythematosus overlap syndrome","volume":"45","author":"Alharbi","year":"2018","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib41","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0022-3476(83)80706-9","article-title":"Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification","volume":"103","author":"Bowyer","year":"1983","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.rdc.2023.01.001_bib42","doi-asserted-by":"crossref","first-page":"102533","DOI":"10.1016\/j.autrev.2020.102533","article-title":"Calcinosis biomarkers in adult and juvenile dermatomyositis","volume":"19","author":"Chung","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.rdc.2023.01.001_bib43","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S1090-3798(98)80021-4","article-title":"Childhood dermatomyositis: clinical course of 36 patients treated with low doses of corticosteroids","volume":"2","author":"Tabarki","year":"1998","journal-title":"Eur J Paediatr Neurol"},{"issue":"9","key":"10.1016\/j.rdc.2023.01.001_bib44","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3899\/jrheum.211393","article-title":"Management of calcinosis cutis in rheumatic diseases","volume":"49","author":"Elahmar","year":"2022","journal-title":"J\u00a0Rheumatol"},{"issue":"Suppl10","key":"10.1016\/j.rdc.2023.01.001_bib45","first-page":"1777","article-title":"Performance of juvenile scleroderma classification criteria for juvenile systemic sclerosis. results from the jssc inception cohort","volume":"69","author":"Klotsche","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2023.01.001_bib46","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/2397198318790494","article-title":"Are diffuse and limited juvenile systemic sclerosis different in clinical presentation? clinical characteristics of a juvenile systemic sclerosis cohort","volume":"4","author":"Foeldvari","year":"2018","journal-title":"J\u00a0Scleroderma Relat Disord"},{"key":"10.1016\/j.rdc.2023.01.001_bib47","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5301\/jsrd.5000213","article-title":"Controversies: molecular vs. clinical systemic sclerosis classification","volume":"1","author":"Johnson","year":"2016","journal-title":"J\u00a0Scleroderma Relat Disord"},{"key":"10.1016\/j.rdc.2023.01.001_bib48","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/ard.60.4.407","article-title":"Differentiation between primary and secondary Raynaud's phenomenon: a prospective study comparing nailfold capillaroscopy using an ophthalmoscope or stereomicroscope","volume":"60","author":"Anders","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2023.01.001_bib49","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/art.1780390712","article-title":"Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). an immunogenetic, serologic, and clinical analysis","volume":"39","author":"Arnett","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2023.01.001_bib50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1741-7015-11-9","article-title":"Genetics of scleroderma: implications for personalized medicine?","volume":"11","author":"Assassi","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.rdc.2023.01.001_bib51","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nrrheum.2018.23","article-title":"Moving towards a molecular taxonomy of autoimmune rheumatic diseases","volume":"14","author":"Barturen","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib52","first-page":"153","article-title":"Antibody pattern and other criteria for diagnosis and classification of PSS","volume":"15","author":"Burgos-Vargas","year":"1988","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib53","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/rheumatology\/keh156","article-title":"Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis","volume":"43","author":"Cutolo","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2023.01.001_bib54","first-page":"155","article-title":"Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis","volume":"27","author":"Cutolo","year":"2000","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib55","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2023.01.001_bib56","first-page":"118","article-title":"A\u00a0subset of systemic sclerosis but not of systemic lupus erythematosus is defined by isolated anti-Ku autoantibodies","volume":"31","author":"Cavazzana","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib57","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1097\/BOR.0000000000000113","article-title":"Scleroderma: the role of serum autoantibodies in defining specific clinical phenotypes and organ system involvement","volume":"26","author":"Domsic","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib58","first-page":"1826","article-title":"Cutaneous and serologic subsets of systemic sclerosis","volume":"18","author":"Ferri","year":"1991","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib59","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/rheumatology\/keg170","article-title":"The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis","volume":"42","author":"Hesselstrand","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2023.01.001_bib60","doi-asserted-by":"crossref","first-page":"e4713","DOI":"10.1097\/MD.0000000000004713","article-title":"Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations","volume":"95","author":"Hoa","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.rdc.2023.01.001_bib61","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/acr.22163","article-title":"Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement","volume":"66","author":"Kaji","year":"2014","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.rdc.2023.01.001_bib62","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/art.11113","article-title":"American College of Rheumatology Ad Hoc Committee of Immunologic Testing G. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies","volume":"49","author":"Reveille","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2023.01.001_bib63","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1272\/jnms.84.56","article-title":"Circulating anti-nuclear antibodies in systemic sclerosis: utility in diagnosis and disease subsetting","volume":"84","author":"Kuwana","year":"2017","journal-title":"J\u00a0Nippon Med Sch"},{"key":"10.1016\/j.rdc.2023.01.001_bib64","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.semarthrit.2014.11.006","article-title":"Antinuclear antibody-negative systemic sclerosis","volume":"44","author":"Salazar","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2023.01.001_bib65","doi-asserted-by":"crossref","first-page":"e2696","DOI":"10.1371\/journal.pone.0002696","article-title":"Molecular subsets in the gene expression signatures of scleroderma skin","volume":"3","author":"Milano","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.rdc.2023.01.001_bib66","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/jid.2013.130","article-title":"Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis","volume":"133","author":"Hinchcliff","year":"2013","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib67","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0049-0172(99)80036-5","article-title":"Nail fold capillaroscopy: normal findings in children and adolescents","volume":"29","author":"Terreri","year":"1999","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl 100","key":"10.1016\/j.rdc.2023.01.001_bib68","first-page":"193","article-title":"Nailfold videocapillaroscopy in healthy children and adolescents: description of normal patterns","volume":"34","author":"Piotto","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib69","first-page":"1081","article-title":"Predicting cardiopulmonary involvement in patients with systemic sclerosis: complementary value of nailfold videocapillaroscopy patterns and disease-specific autoantibodies","volume":"56","author":"Markusse","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2023.01.001_bib70","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10067-005-0041-0","article-title":"Different clinical features in patients with limited and diffuse cutaneous systemic sclerosis","volume":"25","author":"Ostojic","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib71","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5114\/reum.2017.66683","article-title":"Nailfold digital capillaroscopic findings in patients with diffuse and limited cutaneous systemic sclerosis","volume":"55","author":"Shenavandeh","year":"2017","journal-title":"Reumatologia"},{"key":"10.1016\/j.rdc.2023.01.001_bib72","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00005792-200203000-00005","article-title":"Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival","volume":"81","author":"Scussel-Lonzetti","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.rdc.2023.01.001_bib73","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/BOR.0000000000000443","article-title":"Progress in the clinical classification of systemic sclerosis","volume":"29","author":"Johnson","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib74","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/03009742.2017.1299793","article-title":"There is a need for new systemic sclerosis subset criteria. a content analytic approach","volume":"47","author":"Johnson","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib75","first-page":"276","article-title":"A\u00a0survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease","volume":"15","author":"Barnett","year":"1988","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib76","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.3899\/jrheum.100316","article-title":"Anti-Th\/To are common antinucleolar autoantibodies in Italian patients with scleroderma","volume":"37","author":"Ceribelli","year":"2010","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib77","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3899\/jrheum.100754","article-title":"Antinuclear antibodies and clinical associations in a british cohort with limited cutaneous systemic sclerosis","volume":"38","author":"Gliddon","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib78","first-page":"1196","article-title":"Studies of HLA-DR and DQ alleles in systemic sclerosis patients with autoantibodies to RNA polymerases and U3-RNP (fibrillarin)","volume":"27","author":"Falkner","year":"2000","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib79","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1756-185X.2011.01688.x","article-title":"South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome","volume":"15","author":"Graf","year":"2012","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.rdc.2023.01.001_bib80","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2133.2007.08392.x","article-title":"The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis","volume":"158","author":"Hamaguchi","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib81","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.3899\/jrheum.100402","article-title":"Anticentromere-A and anticentromere-B antibodies show high concordance and similar clinical associations in patients with systemic sclerosis","volume":"37","author":"Hanke","year":"2010","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib82","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1046\/j.1365-2249.1999.00964.x","article-title":"Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis","volume":"117","author":"Harvey","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.rdc.2023.01.001_bib83","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3899\/jrheum.120264","article-title":"New centromere autoantigens identified in systemic sclerosis using centromere protein microarrays","volume":"40","author":"Song","year":"2013","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib84","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3899\/rheum.111133","article-title":"Clinical correlates of CENP-A and CENP-B antibodies in a large cohort of patients with systemic sclerosis","volume":"39","author":"Hudson","year":"2012","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib85","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1002\/art.21232","article-title":"Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis","volume":"52","author":"Kuwana","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2023.01.001_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.1780260101","article-title":"Anticentromere antibody. clinical correlations and association with favorable prognosis in patients with scleroderma variants","volume":"26","author":"McCarty","year":"1983","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2023.01.001_bib87","first-page":"248","article-title":"Anticentromere autoantibodies. Evaluation of an ELISA using recombinant fusion protein CENP-B as antigen","volume":"37","author":"Vazquez-Abad","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2023.01.001_bib88","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF02686081","article-title":"Increased prevalence of anti-third generation cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis and CREST syndrome","volume":"32","author":"Wu","year":"2007","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.rdc.2023.01.001_bib89","first-page":"911","article-title":"Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis","volume":"13","author":"Giordano","year":"1986","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib90","first-page":"1528","article-title":"Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA","volume":"34","author":"Santiago","year":"2007","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib91","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/rheumatology\/kep290","article-title":"Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay","volume":"48","author":"Satoh","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2023.01.001_bib92","first-page":"219","article-title":"Nailfold capillaroscopy abnormalities correlate with cutaneous and visceral involvement in systemic sclerosis patients","volume":"34","author":"Sato","year":"2009","journal-title":"Acta Reumatol Port"},{"key":"10.1016\/j.rdc.2023.01.001_bib93","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/intimm\/dxp008","article-title":"Naturally occurring and disease-associated auto-antibodies against topoisomerase I: a fine epitope mapping study in systemic sclerosis and systemic lupus erythematosus","volume":"21","author":"Simon","year":"2009","journal-title":"Int Immunol"},{"issue":"Suppl 106","key":"10.1016\/j.rdc.2023.01.001_bib94","first-page":"98","article-title":"Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis","volume":"35","author":"Iniesta Arandia","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 113","key":"10.1016\/j.rdc.2023.01.001_bib95","first-page":"109","article-title":"To what extent do autoantibodies help to identify high-risk patients in systemic sclerosis?","volume":"36","author":"Boonstra","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib96","doi-asserted-by":"crossref","first-page":"rky002","DOI":"10.1093\/rap\/rky002","article-title":"Distinctive clinical phenotype of anti-centromere antibody-positive diffuse systemic sclerosis","volume":"2","author":"Caetano","year":"2018","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.rdc.2023.01.001_bib97","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jbspin.2014.03.009","article-title":"Antinuclear autoantibody profile in systemic sclerosis patients who are negative for anticentromere and anti-topoisomerase I specificities","volume":"82","author":"Caramaschi","year":"2015","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.rdc.2023.01.001_bib98","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ejim.2013.06.013","article-title":"Clinical significance of autoantibodies to the pericentromeric heterochromatin protein 1a protein","volume":"24","author":"Coppo","year":"2013","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.rdc.2023.01.001_bib99","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1136\/annrheumdis-2018-212999","article-title":"Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer","volume":"77","author":"Igusa","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2023.01.001_bib100","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1111\/1756-185X.13060","article-title":"Relevance of clinical and autoantibody profiles in systemic sclerosis among Thais","volume":"20","author":"Foocharoen","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.rdc.2023.01.001_bib101","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/art.38994","article-title":"Clinical and immunologic predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase III autoantibodies","volume":"67","author":"Hamaguchi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib102","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3899\/jrheum.160833","article-title":"Proteomic analysis of sera from individuals with diffuse cutaneous systemic sclerosis reveals a multianalyte signature associated with clinical improvement during imatinib mesylate treatment","volume":"44","author":"Haddon","year":"2017","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib103","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/ijd.13032","article-title":"RNA polymerase III autoantibodies may indicate renal and more severe skin involvement in systemic sclerosis","volume":"55","author":"Terras","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib104","doi-asserted-by":"crossref","first-page":"R72","DOI":"10.1186\/ar4249","article-title":"Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis","volume":"15","author":"Perosa","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rdc.2023.01.001_bib105","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3109\/08916934.2015.1077231","article-title":"Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects","volume":"48","author":"Wodkowski","year":"2015","journal-title":"Autoimmunity"},{"key":"10.1016\/j.rdc.2023.01.001_bib106","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1002\/art.27549","article-title":"Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I\/III antibodies","volume":"62","author":"Shah","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2023.01.001_bib107","first-page":"S-177","article-title":"Anti-SSA\/Ro52 autoantibodies in scleroderma: results of an observational, cross-sectional study","volume":"32","author":"Sanchez-Montalva","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib108","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.40893","article-title":"Protective effect against cancer of antibodies to the large subunits of both RNA polymerases I and III in scleroderma","volume":"71","author":"Shah","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib109","doi-asserted-by":"crossref","first-page":"11","DOI":"10.14412\/1996-7012-2019-1-11-18","article-title":"Mixed connective tissue disease","volume":"13","author":"Shayakhmetova","year":"2019","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib110","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1002\/art.39316","article-title":"Interpretation of an extended autoantibody profile in a well-characterized australian systemic sclerosis (scleroderma) cohort using principal components analysis","volume":"67","author":"Patterson","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib111","doi-asserted-by":"crossref","first-page":"e3931","DOI":"10.1097\/MD.0000000000003931","article-title":"Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease","volume":"95","author":"Perosa","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.rdc.2023.01.001_bib112","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1093\/rheumatology\/kev234","article-title":"Specific autoantibody profiles and disease subgroups correlate with circulating micro-RNA in systemic sclerosis","volume":"54","author":"Wuttge","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2023.01.001_bib113","first-page":"S131","article-title":"Monospecific anti-Ro52\/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival","volume":"33","author":"Wodkowski","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.001_bib114","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/08916934.2017.1357699","article-title":"Disease-related autoantibody profile in patients with systemic sclerosis","volume":"50","author":"Liaskos","year":"2017","journal-title":"Autoimmunity"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X23000017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X23000017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:30:27Z","timestamp":1760182227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X23000017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":114,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0889857X23000017"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2023.01.001","relation":{},"ISSN":["0889-857X"],"issn-type":[{"type":"print","value":"0889-857X"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Approach to Systemic Sclerosis Patient Assessment","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2023.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}